Shengshi Taikang once again ranks among the "Top 50 Most Influential Companies in China's Healthcare Sector."

Recently, CHC Medical Consulting, in collaboration with CITIC Securities, officially unveiled the "2023 China Healthcare and Greater Health Industry Investment & Financing Honor List." As an innovative pharmaceutical company already in the commercialization phase, Shengshi Taikang once again Ranked on the list of this category, Obtain 2023 China's Top 50 Most Influential Healthcare Companies Award 。

The "Annual China Healthcare Industry Investment and Financing Honor List" is jointly launched by CHC Healthcare Consulting and CITIC Securities, offering an authoritative, third-party perspective on the healthcare sector. Since the inaugural list was unveiled in 2018, the Honor List has become one of the key indicators shaping the development and investment landscape of China's healthcare industry. Beyond recognizing and celebrating those who have significantly contributed to the growth of the healthcare sector, the list also serves as a powerful source of encouragement and motivation for the entire industry, reflecting its forward-thinking values and positive energy.

Shengshi Taikе has once again been recognized on the list of China's 50 Most Influential Healthcare Companies this year, thanks to its ability to rise above challenges in an industry that hasn’t been particularly optimistic over the past two years—and continue delivering groundbreaking innovations. Earlier last year, the company’s independently developed next-generation, highly selective DPP-4 inhibitor, Senglitin (formerly known as Shenglitin), received acceptance of its New Drug Application by the National Medical Products Administration. Internationally renowned diabetes expert and Director of the Department of Endocrinology at Peking University People’s Hospital, Professor Li-Nong Ji, recently unveiled the Phase III clinical trial data and results for Senglitin, revealing that, compared to existing similar drugs already on the market, Its "dose-reduced, twice-the-effect" therapeutic efficacy holds the promise of becoming the best-in-class diabetes medication. Even more remarkable is that, Its safety further addresses the common adverse reactions seen in already marketed products. Currently, The product has entered its final review stage and, once successfully launched, will provide patients in China—our country with a high prevalence of diabetes—more effective and safer options for blood sugar management. Meanwhile, the company has also established a comprehensive strategic layout focused on oral medications and related diseases, centering around globally recognized key targets for diabetes treatment.

In the oncology space, four of the company's pipeline anti-cancer drugs have already entered the clinical stage, with two of them having completed dual submissions in China and the U.S., marking a solid step forward for the company’s innovative drugs as they go global. Among these, CGT-1881 is a globally acclaimed CXCR4-targeted drug used in therapeutic areas such as hematopoietic stem cell mobilization. It is the only domestically developed, original small-molecule oral CXCR4 antagonist, offering patients improved medication adherence. CXCR4 (chemokine receptor), a hotspot target in global drug development, not only plays a critical role in cancer but is also closely linked to several immune diseases, genetic disorders, and viral infections. Currently, CGT-1881 is steadily advancing its clinical trial studies in healthy volunteers as well as patients with non-Hodgkin lymphoma or multiple myeloma.

Founded in 2010 in Suzhou Industrial Park, Shengshi Taikang boasts a core team with decades of global experience spanning the entire lifecycle of pharmaceutical products. The company is dedicated to the research, development, and industrialization of high-quality, differentiated small-molecule innovative drugs. Leveraging an integrated drug R&D technology platform and a diverse business perspective, Shengshi Taikang has built a robust pipeline of cutting-edge therapies, targeting key therapeutic areas such as diabetes management, cancer treatment, and autoimmune diseases.